Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory and Autoimmune Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IL-1 Beta/IL1B drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL1B Mature Protein (aa 117-269) – Wild-type & Mutant. High purity (>95%), Endotoxin Controlled (<1EU/ug). Sequence Verified. HEK293 Expressed. | View IL1B Products |
| Gene Delivery | IL1B Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. | View IL1B Products |
| Benchmark Ab | Anti-IL1B (Sequence of Canakinumab). Recombinant positive control for neutralization assays. | View IL1B Products |
| Validator | IL1B siRNA Set. For knockdown verification. | View IL1B Products |
| NLRP3 | Upstream inflammasome complex driving IL1B maturation. | View NLRP3 Products |
| IL-1R1 | Primary signaling receptor for IL1B binding. | View IL-1R1 Products |
| IL-1A (IL-1 Alpha) | Sister cytokine for cross-reactivity profiling. | View IL-1A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Endotoxin Interference in Cellular Assays | Strictly controlled Endotoxin (<1EU/ug) to prevent false-positive NF-kB activation. |
| Species Cross-Reactivity (Cyno/Mouse/Human) | Human, Mouse, Cynomolgus ortholog proteins available with >95% purity, Sequence Verified. |
| Family Specificity (vs IL-1A/IL-1RA) | High-purity homologous panel proteins strictly verified by mass spec for counter-screening. |
| Neutralizing Potency Validation | Clinical Benchmark Antibodies (Canakinumab biosimilar) included for assay standardization. |
Live IL-1 Beta R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL-1 Beta (IL1B) therapeutics is intensifying, with major players shifting focus from traditional mAbs for rare autoinflammatory syndromes to broader indications like cardiovascular disease, gout, and tumor microenvironment modulation. Following the landmark CANTOS trial demonstrating cardiovascular risk reduction, the target has re-emerged as a central node in inflammation-driven pathology. As first-generation therapies (Canakinumab, Rilonacept) reach the clinic and establish baseline efficacy, the next wave of R&D is targeting highly potent, extended half-life antibodies for Sub-Q administration, bispecific modalities designed to simultaneously neutralize IL-1B and other synergistic inflammatory cytokines (e.g., IL-1α), as well as upstream inflammasome modulation via NLRP3 inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Novartis, XOMA | Gout, CAPS, Cardiovascular | Neutralization Assay (Need endotoxin-controlled active antigens) |
| Cytokine Trap / Fusion Protein | Kiniksa, Regeneron | Pericarditis, RA | Kinetics/Affinity (Need multi-species mature IL1B proteins) |
| Small Molecule (Upstream) | Roche, NodThera, Novartis, Vividion | Neuroinflammation, NLRP3-driven diseases | Downstream Readout (Need Benchmark Abs to validate IL1B blockade) |
| Bispecific Antibody | Various Biotechs | Oncology, Severe Asthma, Dual IL-1α/β neutralization | Cross-reactivity Panel (Need IL-1A/IL1B/IL-1R1 verified proteins) |